Two pharmaceutical cases highlight recent developments in Canadian patent law relating to duty of candour during patent prosecution and patent claim construction, says Katie Wang.
Duty of candour
A recent case from the Federal Court in Canada has highlighted the importance of duty of candour during prosecution and closely scrutinising the file wrapper in assessing patent validity.
The duty of candour is a well-established doctrine in the United States. It requires every party to a patent application, including a patent applicant and its agents, to disclose to the United States Patent and Trademarks Office all publications that they know of that may adversely affect the patentability of their invention.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Canada, patent law, pharmaceuticals, duty of candour, Wenk
